Impact of symptom control on health-related quality of life in atrial fibrillation patients: the psychologist's viewpoint
Key result
Flecainide controlled-release treatment in uncontrolled paroxysmal atrial fibrillation patients led to greater improvements in quality of life at 6 months compared to controlled patients.
Why the study?
Does symptom control improve health-related quality of life in patients with atrial fibrillation?
Population
Patients with atrial fibrillation, particularly paroxysmal atrial fibrillation (PAF)
Comparison
Symptom control strategies vs Uncontrolled symptoms or healthy matched controls
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
This editorial highlights that symptom control is central to improving quality of life in AF patients, emphasizing the need for objective monitoring to accurately assess AF burden and treatment efficacy.
Structured PICO
Does symptom control improve health-related quality of life in patients with atrial fibrillation?
P
Population
Patients with atrial fibrillation, particularly paroxysmal atrial fibrillation (PAF)
I
Intervention
Symptom control strategies (including pharmacological rate/rhythm control and catheter ablation)
C
Comparator
Uncontrolled symptoms or healthy matched controls
O
Outcome
Health-related quality of life (QoL)patient reported
This editorial highlights that symptom control is central to improving quality of life in AF patients, emphasizing the need for objective monitoring to accurately assess AF burden and treatment efficacy.
Limitations
- Self-reported episodes may not truly represent AF burden due to undetected asymptomatic episodes.
- Differences in QoL may reflect adaptation to a newly diagnosed condition rather than treatment effect.
- Difficult to distinguish between psychological placebo effects and true benefits of symptom control using subjective measures.
- Reliance on subjective measures of AF burden
- Difficulty distinguishing between psychological placebo effects and true benefits of symptom control
- Asymptomatic episodes may go undetected but still impact QoL
Cite This Study
Smith et al. (2010) conducted an editorial in Paroxysmal atrial fibrillation. Flecainide acetate-controlled release vs. Controlled paroxysmal atrial fibrillation was evaluated on Quality of life (SF-36). Flecainide controlled-release treatment in uncontrolled paroxysmal atrial fibrillation patients led to greater improvements in quality of life at 6 months compared to controlled patients.